Glenmark Pharma unveils triple FDC Zita-PioMet for Type 2 diabetes in India

On occasion of the launch, Alok Malik, EVP & Business Head ‐ India Formulations, Glenmark Pharmaceuticals Ltd., said, "Type 2 diabetes patients in India often face issues of beta cell dysfunction along with insulin resistance. In fact, the prevalence of high insulin resistance in India is 38% compared to the global incidence of 15%. Being a leader in diabetes therapy in the country, we are proud to introduce Zita-PioMet, India's first triple fixed-dose combination for high insulin-resistant type 2 diabetes. The innovative, effective, and affordable drug will help improve the glycemic control among adult patients with high HbA1c."

In 2015, Glenmark launched the DPP4 inhibitor, Teneligliptin (Zita Plus and Ziten), followed by a FDC of Teneligliptin + Metformin (Zita-Met Plus and Ziten-M). Glenmark later launched Remogliflozin (Remo and Remozen), a novel SGLT‐2 inhibitor in 2019, and subsequently, its combinations with Metformin and Vildagliptin (Remo-V, Remozen-V, Remo MV, and Remozen MV). Earlier in 2022, Glenmark also launched Sitagliptin (Sitazit) and its FDCs, followed by Lobeglitazone (LOBG) and FDCs of Teneligliptin including its combinations with Pioglitazone (Zita Pio) and Dapagliflozin (Zita-D).